C-reactive protein and coronary atheroma regression following statin therapy: A meta-regression of randomized controlled trials

Darui Gao, Rong Hua, Dina Jiesisibieke, Yanjun Ma, Chenglong Li, Sijing Wu, Qian Ma, Wuxiang XieFrontiers in Cardiovascular Medicine 2022 · DOI

TL;DR

This meta-analysis of randomized controlled trials (RCTs) demonstrates that statin therapy significantly reduces coronary plaque volume. Crucially, the degree of plaque regression is strongly associated with the reduction in C-reactive protein (CRP/hsCRP), suggesting that statins' anti-inflammatory effects play a key role in their plaque-stabilizing benefits, potentially independent of their LDL-lowering capacity.

What Problem Does This Paper Address?

Coronary heart disease (CHD) is a leading cause of death globally, with atherosclerosis – the buildup of plaque in arteries – being its primary driver. While statins are well-established for lowering LDL cholesterol and preventing cardiovascular events, their precise mechanisms in promoting plaque regression remain an area of active research. Previous studies have shown statins can stabilize and even reverse atherosclerotic plaques, but findings on the influencing factors have been inconsistent. Specifically, the role of statins' anti-inflammatory properties, often indicated by C-reactive protein (CRP) levels, in achieving plaque regression, independent of lipid-lowering effects, needed further clarification. This paper aims to quantify the effect of statins on coronary plaque volume and investigate the relationship between CRP/hsCRP reduction and plaque regression.

Methods

The researchers conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) that assessed the impact of statin therapy on coronary plaque volume. They searched PubMed, EMBASE, and the Cochrane Library for studies published up to June 15, 2022. Inclusion criteria specified RCTs using intravascular ultrasound (IVUS) to measure plaque volume (total atheroma volume - TAV, percent atheroma volume - PAV, or plaque volume - PV), with follow-up periods of at least six months, and reporting LDL-C and CRP/hsCRP levels before and after treatment.

A meta-analysis was performed to pool the effect of statins on changes in TAV/PV and PAV. To explore the relationship between plaque regression and other factors, a meta-regression analysis was employed. This analysis investigated the association between the percent change in CRP/hsCRP, percent change in LDL-C, age, gender, and study duration, and the changes in TAV/PV and PAV.

Datasets

The study did not introduce new datasets. Instead, it synthesized data from 12 previously published randomized controlled trials. The data extracted from these trials included:

  • Study characteristics (author, publication year, country, duration)
  • Patient characteristics (age, sex)
  • Intervention details (statin type and dose)
  • Outcome measures (TAV, PAV, PV, LDL-C, CRP/hsCRP at baseline and endpoint)

Key Insights and Ideas

  • Statins are effective plaque reducers: The meta-analysis confirmed that statin therapy significantly reduces coronary plaque volume, as measured by both TAV/PV and PAV.
  • Anti-inflammatory effect is key: The most striking finding is the strong association between the reduction in CRP/hsCRP levels and the degree of plaque regression. This suggests that statins' anti-inflammatory actions are a significant driver of their beneficial effects on atherosclerotic plaques.
  • Independence from LDL-C: Interestingly, the meta-regression analysis indicated that the percent change in LDL-C was not significantly associated with plaque regression (TAV/PV or PAV) when considered independently or in multivariate models, especially when CRP/hsCRP reduction was accounted for. This challenges the long-held view that LDL-C reduction is the sole or primary mechanism for statin-induced plaque regression.
  • CRP/hsCRP as a therapeutic target: The findings highlight CRP/hsCRP as a potential therapeutic target for managing atherosclerosis, emphasizing the importance of statins' pleiotropic, anti-inflammatory effects.

Key Results

  • TAV/PV Reduction: A meta-analysis of 15 statin-treated arms showed a significant reduction in TAV/PV compared to control arms (Standardized Mean Difference (SMD): -0.27, 95% CI: -0.42 to -0.12, p < 0.001).
  • PAV Reduction: A meta-analysis of 7 trials found a significant reduction in PAV in the statin group (SMD: -0.16, 95% CI: -0.29 to -0.03, p = 0.019).
  • Meta-Regression (TAV/PV):
    • Percent change of CRP/hsCRP was significantly associated with a reduction in TAV/PV (Model 1: β = 0.0064, p = 0.024).
  • This association remained significant even after adjusting for percent change of LDL-C, age, gender, and study duration (Model 4: β = 0.0116, p = 0.023).
  • Percent change of LDL-C was not significantly associated with TAV/PV change.
  • Meta-Regression (PAV):
    • Percent change of CRP/hsCRP was significantly associated with a reduction in PAV (Model 1: β = 0.0086, p = 0.009).
  • However, this association was not significant after adjusting for other covariates (Model 4). The authors note this might be due to the limited number of trials (7) included in this specific regression.

Limitations and Future Work

The authors acknowledge several limitations:

  • Database Search: The study relied on three major databases, potentially missing relevant studies from other sources or gray literature.
  • Blinding: Not all included RCTs were double-blinded, which could introduce performance bias.
  • Meta-Regression Power: The meta-regression for PAV change, using only 7 trials, may have insufficient statistical power.
  • Aggregate Data: The analysis used aggregate study-level data rather than individual patient-level data, which could limit the precision and integrity of the findings.

Future research directions suggested include:

  • Further investigation into the direct correlation between CRP levels and atherosclerosis extension using imaging techniques.
  • Continued exploration of statins' anti-inflammatory effects and their role in plaque regression, potentially identifying CRP/hsCRP as a therapeutic target.
  • Future studies could benefit from individual patient-level data to refine regression models and better understand the relationship between CRP/hsCRP and plaque regression.

Summary updated

Abstract

In conclusion, statin therapy is beneficial for plaque regression. Statins promote plaque regression, which might be associated to their anti-inflammatory ability.
BibTeX
@inproceedings{gao2022c,
  author = {Darui Gao and Rong Hua and Dina Jiesisibieke and Yanjun Ma and Chenglong Li and Sijing Wu and Qian Ma and Wuxiang Xie},
  title = {{C-reactive protein and coronary atheroma regression following statin therapy: A meta-regression of randomized controlled trials}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2022},
  doi = {10.3389/fcvm.2022.989527},
}
Figure